

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Undermark Office Armost Charles and Fraction West Management (Commerce Commerce Comme

APPLICATION NO	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO	CONTRMATION NO	
10.054,967	01/25/2002	Brent I. Kreider	Geider 1488/034000B 910 <sup>m</sup>		
22198	(State) 3 (1.1.2) in 3				
HUMAN GENOME SCIENCES INC			EXAMINER		
9410 KEY WEST AVENUE ROCKVILLE, MD 20850			KEMMERER.	ELIZABETH	
			ART UNIT	PAPER NUMBER	
			16.46		

DATE MAILED | 03/11/2003

Please find below and or attached an Office communication concerning this application or proceeding.

			Application	No.	Applicant(s)				
			10/054,967		KREIDER ET AL.				
	Office Action Summary		Examiner		Art Unit				
				Kemmerer, Ph.D.	1646				
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address								
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM									
THE N - Exten after S - If the - If NO - Failur - Apy re	DRTENED STATUTORY PERIOD IN MAILING DATE OF THIS COMMUN sions of time may be available under the provision SIK (6) MONTHS from the mailing date of this comperiod for reply spell field above is less than thirty (ill period for reply is specified above, the maximum significant of the period for reply within the set or extended period for reply received by the idiffice later than three months of catent term adjustment. See 37 CFR 1.704(b)	IICATION is of 37 CFR imunication 30) days, a r statutory peri	N. 1.136(a) In no eveni reply within the statute od will apply and will e	t, however, may a reply be to ory minimum of thirty (30) da expire SIX (6) MONTHS from ation to become ABANDON	mely filed  ys w.ll be considered timely  the mailing date of this communication.  ED (35 U.S.C. § 130).				
1)[	Responsive to communication(s) f	filed on 2	6 February 200	<u>)3</u> .					
2a)[_	This action is <b>FINAL</b> .		 This action is n						
3)[]	Since this application is in condition	on for allo	wance except	for formal matters, p	prosecution as to the merits is				
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims									
•	Claim(s) 41-230 is/are pending in	the applic	cation.						
	4a) Of the above claim(s) is/are withdrawn from consideration.								
5)									
,	6) Claim(s) is/are rejected.								
7)									
,	Claim(s) <u>41-230</u> are subject to rest	triction ar	nd/or election re	equirement.					
	on Papers								
9)	The specification is objected to by t	he Exam	iner.						
10)[	The drawing(s) filed on is/are								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
11)	The proposed drawing correction fil	ed on	is: a) <u> </u> ap	proved b) disapp	roved by the Examiner.				
	If approved, corrected drawings are i	required in	reply to this Off	ice action.					
12) The oath or declaration is objected to by the Examiner.									
Priority under 35 U.S.C. §§ 119 and 120									
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).									
a)	a) All b) Some * c) None of:								
	1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
<ul> <li>Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>See the attached detailed Office action for a list of the certified copies not received.</li> </ul>									
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).									
a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.									
Attachment(s)									
	ce of References Cited (PTO-892)				ary (PTO-413) Paper Nois)				
2) Noti	ce of Draftsperson's Patent Drawing Review rmation Disclosure Statement's (PTO-1449)	, (PTO-948 : Paper No	: :S:		al Patent Application (PTO-152)				
PTO-326 - R	transmanutmin e. 04-01:	Offic	ce Action Summa	гу	Part of Paper No. 8				

Art Unit: 1646

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 41-135, drawn to methods of inhibiting activation or mobilization of eosinophils comprising administering one of a number of peptides, each of which at least comprise SEQ ID NO: 23, classified in class 514, subclass
   2.
- II. Claims 136-230, drawn to methods of inhibiting activation or mobilization of basophils comprising administering one of a number of peptides, each of which at least comprise SEQ ID NO: 23, classified in class 514, subclass 2.

The inventions are distinct, each from the other because of the following reasons:

Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive groups that are directed to different methods, restriction is deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons: Groups I and II are directed to methods that are distinct both physically and functionally, and are not required one for the other. Invention I requires inhibition of eosinophils, which is not required by the other group. Invention II requires inhibition of basophils, which is not required by the other group. The art recognizes that eosinophils and basophils are

Application/Control Number: 10/054,967

Art Unit: 1646

significantly different, in that eosinophils are involved in response to parasitic infection, whereas basophils are not (see Stedman's Medical Dictionary definition, enclosed).

Therefore, the patient populations for which the two Inventions are useful are completely different, warranting a separate search.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter and separate search requirements, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth C. Kemmerer, Ph.D. whose telephone number is (703) 308-2673. The examiner can normally be reached on Mon. - Thurs., 6:30 to 4:00, and alternate Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne L. Eyler, Ph.D. can be reached on (703) 308-6564. The fax phone numbers for the organization where this application or proceeding is assigned are (703)

Application/Control Number: 10/054,967

Art Unit: 1646

Page 4

Control of

872-9306 for regular communications and (703) 872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

ECK

March 11, 2003